ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efpeglenatide

Also written as “HM11260C”, “Efpeglenatide SAR439977” and “efpeglenatide (SAR439977)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by 2 companies.

Drug pageEfpeglenatide: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 21, 201713 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceuticalits history only91 open or runningphase 3since Nov 21, 2017Mar 23, 2010Nov 2027phase 3 · NCT07379333
Sanofi40 open or runningphase 3since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2018First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT03496298 · 4,076 enrolled · United States, Argentina, Bulgaria and more
  2. Sep 24, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03684642 · 908 enrolled · United States, Hungary, Poland and more
  3. Oct 18, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03713684 · 370 enrolled · United States, China, Korea, Republic of
  4. Dec 7, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03770728 · 312 enrolled · United States, China, Taiwan

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319

Studies

All 4 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03770728Diabetes Mellitus, Type 2 · United States, China, Taiwan3TerminatedNov 28, 2020312
NCT03713684Diabetes Mellitus, Type 2 · United States, China, Korea, Republic of3TerminatedNov 20, 2020370
NCT03684642Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more3TerminatedOct 13, 2020908
NCT03496298Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more3TerminatedDec 10, 20204,076

How it is read

Names in the registry

  • “HM11260C”, 12 entries
  • “Efpeglenatide SAR439977”, 2 entries
  • “efpeglenatide (SAR439977)”, 1 entry
  • “Efpeglenatide”, 1 entry
  • “Efpeglenatide (SAR439977)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.